Bimekizumab

Drug Profile

Bimekizumab

Alternative Names: CDP-4940; UCB-4940

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors; IL17F protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • No development reported Psoriasis

Most Recent Events

  • 17 Aug 2017 UCB Biopharma plans a phase II trial for Hidradenitis suppurativa (NCT03248531)
  • 21 Jul 2017 Adverse event and efficacy data released by UCB from the phase IIb BE ABLE trial in Plaque psoriasis, which met the primary endpoint
  • 05 Jul 2017 UCB Biopharma plans a phase II trial for Ankylosing spondylitis (Treatment-experienced) (NCT03215277)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top